OS Therapies Incorporated (OSTX) - Total Liabilities
Based on the latest financial reports, OS Therapies Incorporated (OSTX) has total liabilities worth $4.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OS Therapies Incorporated annual equity growth to track the company's year-over-year net asset growth rate.
OS Therapies Incorporated - Total Liabilities Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's total liabilities have evolved over time, based on quarterly financial data.
OS Therapies Incorporated Competitors by Total Liabilities
The table below lists competitors of OS Therapies Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bever Holding NV
AS:BEVER
|
Netherlands | €13.49 Million |
|
Gokul Refoils and Solvent Limited
NSE:GOKUL
|
India | Rs5.51 Billion |
|
Honmyue Enterprise Co Ltd
TW:1474
|
Taiwan | NT$1.54 Billion |
|
Toplus Global Co Ltd
TWO:3522
|
Taiwan | NT$1.81 Billion |
|
EYG Gayrimenkul Yatirim Ortakligi A.S.
IS:EYGYO
|
Turkey | TL758.51 Million |
|
MeVis Medical Solutions AG
XETRA:M3V
|
Germany | €8.06 Million |
|
Oceanpal Inc
NASDAQ:OP
|
USA | $4.10 Million |
|
Adaptimmune Therapeutics plc
F:473A
|
Germany | €201.59 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down OS Therapies Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of OS Therapies Incorporated.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OS Therapies Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OS Therapies Incorporated (2020–2024)
The table below shows the annual total liabilities of OS Therapies Incorporated from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.73 Million | -80.95% |
| 2023-12-31 | $24.81 Million | +37.35% |
| 2022-12-31 | $18.07 Million | +53.40% |
| 2021-12-31 | $11.78 Million | -99.85% |
| 2020-12-31 | $8.00 Billion | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more